About this FactMed analysis covering adverse side effect reports of ALMARL patients who developed PLEURISY.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 2 individuals taking ALMARL reported PLEURISY to the FDA. A total of 227 ALMARL drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALMARL and PLEURISY. In doing so, we compare ALMARL with other drugs that cause PLEURISY, to help you evaluate whether or not ALMARL causes PLEURISY. Likewise, this page shows the most highly-reported side effects of ALMARL, so you can see if PLEURISY ranks among ALMARL's most well-known side effects.
Summary Statistics
Reports of ALMARL causing PLEURISY: 2
Reports of any side effect of ALMARL : 227
Percentage of ALMARL patients where PLEURISY is a reported side effect: 0.8811%

FDA reports of any drug causing PLEURISY : 3137
Average percentage for all medicated patients where PLEURISY is reported as a complication: 0.0197%

Physician opinion on ALMARL as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALMARL:
HYPERTENSION ( 76 patients )
PARKINSON'S DISEASE ( 8 patients )
ESSENTIAL TREMOR ( 6 patients )
ATRIAL FIBRILLATION ( 4 patients )
SCHIZOPHRENIA ( 2 patients )
TREMOR ( 2 patients )
ANGINA PECTORIS ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
PALPITATIONS ( 2 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 2 patients )
TACHYCARDIA ( 2 patients )
HYPERTROPHY ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with PLEURISY:

FOSAMAX (452 patients)
METHOTREXATE (405 patients)
HUMIRA (366 patients)
PREDNISOLONE (318 patients)
REMICADE (310 patients)
ENBREL (221 patients)
ACCUTANE (219 patients)
VIOXX (215 patients)
ASPIRIN (167 patients)
GOLIMUMAB (159 patients)
TOCILIZUMAB (159 patients)
PREDNISONE (155 patients)
LOVENOX (148 patients)
FOLIC ACID (137 patients)
NUVARING (127 patients)
LASIX (124 patients)
YAZ (113 patients)
ACTEMRA (99 patients)
SEROQUEL (96 patients)
RHEUMATREX (95 patients)
COUMADIN (95 patients)
NEXIUM (93 patients)
ZOLOFT (92 patients)
PREDNISONE TAB (86 patients)
FORTEO (86 patients)
YASMIN (83 patients)
PEGASYS (81 patients)
ZOMETA (81 patients)
SIMVASTATIN (79 patients)
ACETAMINOPHEN (77 patients)
PLACEBO (75 patients)
FUROSEMIDE (74 patients)
PREDONINE (73 patients)
XANAX (73 patients)
ALBUTEROL (72 patients)
VOLTAREN (70 patients)
OMEPRAZOLE (69 patients)
LIPITOR (69 patients)
ADVAIR DISKUS 100/50 (69 patients)
AVONEX (69 patients)
PROTONIX (68 patients)
IBUPROFEN (67 patients)
AMBIEN (65 patients)
SYNTHROID (64 patients)
BLINDED; INFLIXIMAB, RECOMBINANT (64 patients)
GLEEVEC (63 patients)
LOXONIN (61 patients)
ZOCOR (61 patients)
CELEBREX (60 patients)
LEVOTHYROXINE SODIUM (58 patients)
PEG-INTRON (57 patients)
ARAVA (56 patients)
HYDROCHLOROTHIAZIDE (56 patients)
PLAVIX (56 patients)
AMN107 AMN+CAP (56 patients)
NAPROXEN (55 patients)
ZYRTEC (55 patients)
ATIVAN (54 patients)
ZOFRAN (53 patients)
CYTOMEL (53 patients)
LANSOPRAZOLE (52 patients)
SINGULAIR (49 patients)
RIBAVIRIN (49 patients)
POTASSIUM CHLORIDE (48 patients)
CALCIUM (UNSPECIFIED) (47 patients)
FAMOTIDINE (47 patients)
PRILOSEC (46 patients)
ALPRAZOLAM (46 patients)
AREDIA (45 patients)
AMLODIPINE (45 patients)
LISINOPRIL (44 patients)
MEDROL (43 patients)
CLOZARIL (43 patients)
PROZAC (42 patients)
OXYCONTIN (42 patients)
LEXAPRO (41 patients)
NEURONTIN (41 patients)
DECADRON (41 patients)
ALENDRONATE SODIUM (41 patients)
PREMARIN (41 patients)
INFLIXIMAB (40 patients)
METHYLPREDNISOLONE (40 patients)
GLUCOPHAGE (40 patients)
VITAMIN D (40 patients)
RAMIPRIL (39 patients)
VICODIN (39 patients)
DIGOXIN (39 patients)
ALLOPURINOL (39 patients)
TYLENOL (39 patients)
CYMBALTA (38 patients)
COPEGUS (38 patients)
PERCOCET (38 patients)
PREVACID (38 patients)
FLONASE (38 patients)
BYETTA (37 patients)
NEORAL (37 patients)
PLAQUENIL (36 patients)
FLEXERIL (36 patients)
ISONIAZID (36 patients)
AMARYL (36 patients)
FOLIAMIN (35 patients)
ASCORBIC ACID (35 patients)
OXYCODONE HCL (35 patients)
SPIRIVA (35 patients)
SULFASALAZINE (35 patients)
MUCOSTA (34 patients)
VELCADE (34 patients)
ACTONEL (34 patients)
CISPLATIN (34 patients)
TASIGNA (34 patients)
VITAMIN D (UNSPECIFIED) (34 patients)
REBETOL (33 patients)
TYLENOL (CAPLET) (32 patients)
EVISTA (32 patients)
LANTUS (32 patients)
PAXIL (31 patients)
MELOXICAM (31 patients)
WARFARIN SODIUM (31 patients)
CLINDAMYCIN (30 patients)
DILAUDID (30 patients)
DICLOFENAC SODIUM (30 patients)
CRESTOR (30 patients)
REGLAN (30 patients)
TEGRETOL (29 patients)
PROGRAF (29 patients)
CELECOXIB (29 patients)
DIOVAN (29 patients)
CYCLOPHOSPHAMIDE (29 patients)
ZANTAC (29 patients)
NORVASC (29 patients)
EXJADE (29 patients)
COZAAR (29 patients)
AMITRIPTYLINE HCL (29 patients)
VITAMINS (29 patients)
WELLBUTRIN (28 patients)
ROCEPHIN (28 patients)
NITROGLYCERIN (28 patients)
GABAPENTIN (28 patients)
ACYCLOVIR (28 patients)
CALCIUM (28 patients)
EFFEXOR (28 patients)
CORTANCYL (28 patients)
LYRICA (28 patients)
MUCINEX (28 patients)
AZITHROMYCIN (28 patients)
DEMEROL (27 patients)
ORTHO EVRA (27 patients)
RANITIDINE (27 patients)
LORTAB (27 patients)
TOPROL-XL (27 patients)
TYSABRI (27 patients)
HYDROCODONE BITARTRATE (26 patients)
CLONAZEPAM (26 patients)
REBIF (26 patients)
VITAMINS (UNSPECIFIED) (26 patients)
ETANERCEPT (26 patients)
METFORMIN HCL (26 patients)
INSULIN (26 patients)
ZYPREXA (26 patients)
KEFLEX (26 patients)
SPRYCEL (25 patients)
SOLU-MEDROL (25 patients)
AVANDIA (25 patients)
TACROLIMUS (25 patients)
ALEMTUZUMAB (25 patients)
ARANESP (25 patients)
TRAMADOL HCL (24 patients)
ZITHROMAX (24 patients)
VITAMIN B-12 (24 patients)
TRAZODONE HCL (24 patients)
TOPAMAX (23 patients)
REVLIMID (23 patients)
MIDRIN (23 patients)
ALLEGRA (23 patients)
MORPHINE SULFATE (23 patients)
DUONEB (23 patients)
LORAZEPAM (23 patients)
OPTIMARK (22 patients)
CHANTIX (22 patients)
CIPROFLOXACIN (22 patients)
METHOTREXATE SODIUM (22 patients)
ELAVIL (22 patients)
ERYTHROMYCIN (22 patients)
HYDROCODONE (22 patients)
AUGMENTIN '125' (22 patients)
LEVOFLOXACIN (22 patients)
PARACETAMOL (22 patients)
SPIRONOLACTONE (22 patients)
ULTRAM (22 patients)
VENTOLIN (21 patients)
RISPERDAL (21 patients)
RIMATIL (21 patients)
KLOR-CON (21 patients)
MULTI-VITAMIN (21 patients)
AVASTIN (21 patients)
MICARDIS (21 patients)
BACLOFEN (21 patients)
CYANOCOBALAMIN (21 patients)
LOTREL (20 patients)
OXYGEN (20 patients)
ACETASOL (20 patients)
PHENERGAN (20 patients)
DIAZEPAM (20 patients)
FLUOROURACIL (20 patients)
HUMALOG (20 patients)
RABEPRAZOLE SODIUM (20 patients)
MAGNESIUM OXIDE (20 patients)
CIMZIA (20 patients)
CABERGOLINE (20 patients)
CLARAVIS (20 patients)
Most common side effects for patients taking ALMARL:
DEPRESSED LEVEL OF CONSCIOUSNESS (20 patients)
HALLUCINATION (15 patients)
FALL (13 patients)
HYPOGLYCAEMIA (13 patients)
PYREXIA (12 patients)
TREMOR (12 patients)
DIARRHOEA (11 patients)
HEPATIC FUNCTION ABNORMAL (11 patients)
PNEUMONIA (10 patients)
DYSARTHRIA (10 patients)
BLOOD CREATINE PHOSPHOKINASE INCREASED (9 patients)
RENAL FAILURE ACUTE (9 patients)
LIVER DISORDER (9 patients)
CEREBRAL INFARCTION (8 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (8 patients)
DRUG INEFFECTIVE (8 patients)
RENAL IMPAIRMENT (8 patients)
HYPONATRAEMIA (8 patients)
INTERSTITIAL LUNG DISEASE (8 patients)
JAUNDICE (8 patients)
OEDEMA PERIPHERAL (8 patients)
CONDITION AGGRAVATED (7 patients)
DELIRIUM (7 patients)
DYSPHAGIA (7 patients)
DYSPNOEA (7 patients)
HYPOAESTHESIA (7 patients)
RHABDOMYOLYSIS (7 patients)
VOMITING (6 patients)
DELUSION (6 patients)
RESPIRATORY FAILURE (6 patients)
DYSKINESIA (6 patients)
SOMNOLENCE (6 patients)
HEPATIC NEOPLASM MALIGNANT (6 patients)
HYPERGLYCAEMIA (6 patients)
HYPOKALAEMIA (6 patients)
MOVEMENT DISORDER (6 patients)
MUSCULAR WEAKNESS (6 patients)
WHITE BLOOD CELL COUNT INCREASED (5 patients)
BLADDER CANCER (5 patients)
BLOOD ANTIDIURETIC HORMONE INCREASED (5 patients)
RESTLESSNESS (5 patients)
BLOOD OSMOLARITY DECREASED (5 patients)
PLEURAL EFFUSION (5 patients)
C-REACTIVE PROTEIN INCREASED (5 patients)
CONVULSION (5 patients)
RENAL DISORDER (5 patients)
VITH NERVE PARALYSIS (5 patients)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (5 patients)
INTESTINAL OBSTRUCTION (5 patients)
SEPSIS (5 patients)
ROAD TRAFFIC ACCIDENT (5 patients)
MUSCULOSKELETAL PAIN (5 patients)
NAUSEA (5 patients)
ANOREXIA (4 patients)
ATELECTASIS (4 patients)
ATRIAL FIBRILLATION (4 patients)
ATRIOVENTRICULAR BLOCK (4 patients)
BLOOD CREATININE INCREASED (4 patients)
BRADYCARDIA (4 patients)
CARDIAC FAILURE (4 patients)
CONSTIPATION (4 patients)
DECREASED APPETITE (4 patients)
DEHYDRATION (4 patients)
DIZZINESS (4 patients)
PLATELET COUNT DECREASED (4 patients)
PAIN (4 patients)
HYPERTENSION (4 patients)
HYPOTHYROIDISM (4 patients)
ILEUS (4 patients)
METABOLIC ACIDOSIS (4 patients)
SMALL INTESTINE CARCINOMA (4 patients)
URINE OSMOLARITY INCREASED (4 patients)
ABASIA (3 patients)
AGGRESSION (3 patients)
PRURITUS (3 patients)
ANAEMIA (3 patients)
PULMONARY ALVEOLAR HAEMORRHAGE (3 patients)
WHITE BLOOD CELL COUNT DECREASED (3 patients)
ASTHMA (3 patients)
BLOOD BILIRUBIN INCREASED (3 patients)
RENAL FAILURE (3 patients)
BLOOD PRESSURE DECREASED (3 patients)
BLOOD PRESSURE INCREASED (3 patients)
VASCULITIS (3 patients)
CAROTID ARTERY STENOSIS (3 patients)
THERAPEUTIC AGENT TOXICITY (3 patients)
CHILLS (3 patients)
CHROMATURIA (3 patients)
PETECHIAE (3 patients)
CHRONIC LYMPHOCYTIC LEUKAEMIA (3 patients)
PORIOMANIA (3 patients)
RENAL ARTERY STENOSIS (3 patients)
PANCYTOPENIA (3 patients)
DRUG ERUPTION (3 patients)
SUDDEN ONSET OF SLEEP (3 patients)
DRUG WITHDRAWAL SYNDROME (3 patients)
VERTIGO (3 patients)
EPILEPSY (3 patients)
FACE OEDEMA (3 patients)
VOLVULUS (3 patients)
GENERALISED OEDEMA (3 patients)
GINGIVAL BLEEDING (3 patients)
HAEMORRHAGE SUBCUTANEOUS (3 patients)
HALLUCINATION, VISUAL (3 patients)
PSYCHIATRIC SYMPTOM (3 patients)
HEART RATE DECREASED (3 patients)
HELICOBACTER TEST POSITIVE (3 patients)
HEPATITIS FULMINANT (3 patients)
HYPERKALAEMIA (3 patients)
HYPOTENSION (3 patients)
IDIOPATHIC THROMBOCYTOPENIC PURPURA (3 patients)
LOSS OF CONSCIOUSNESS (3 patients)
SENSORY DISTURBANCE (3 patients)
LYMPHOMA (3 patients)
MALAISE (3 patients)
MARKEDLY REDUCED DIETARY INTAKE (3 patients)
RENAL TUBULAR DISORDER (3 patients)
NEOPLASM MALIGNANT (3 patients)
SINUS ARREST (3 patients)
ABDOMINAL DISCOMFORT (2 patients)
ABDOMINAL PAIN (2 patients)
ACUTE MYELOID LEUKAEMIA (2 patients)
STOMACH MASS (2 patients)
PERSONALITY CHANGE (2 patients)
AGITATION (2 patients)
ALTERED STATE OF CONSCIOUSNESS (2 patients)
ANAPHYLACTOID REACTION (2 patients)
ANGER (2 patients)
PRODUCTIVE COUGH (2 patients)
RENAL CYST (2 patients)
APHASIA (2 patients)
ASTHENIA (2 patients)
ATRIOVENTRICULAR BLOCK COMPLETE (2 patients)
THIRST (2 patients)
PROSTATE CANCER (2 patients)
BLOOD AMYLASE INCREASED (2 patients)
BLOOD UREA INCREASED (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
SPEECH DISORDER (2 patients)
TUMOUR LYSIS SYNDROME (2 patients)
CEREBRAL HAEMORRHAGE (2 patients)
CHEST X-RAY ABNORMAL (2 patients)
COLON CANCER (2 patients)
COMA HEPATIC (2 patients)
COMPLETED SUICIDE (2 patients)
CONTUSION (2 patients)
PERFORMANCE STATUS DECREASED (2 patients)
DEFAECATION URGENCY (2 patients)
DEMENTIA ALZHEIMER'S TYPE (2 patients)
RASH PRURITIC (2 patients)
DIABETIC KETOACIDOSIS (2 patients)
DRUG INTERACTION (2 patients)
DRUG LEVEL INCREASED (2 patients)
DYSPEPSIA (2 patients)
DYSSTASIA (2 patients)
ELECTROCARDIOGRAM QT PROLONGED (2 patients)
STEVENS-JOHNSON SYNDROME (2 patients)
EPULIS (2 patients)
EXTRAOCULAR MUSCLE PARESIS (2 patients)
FACIAL PARESIS (2 patients)
FEAR (2 patients)
FEBRILE NEUTROPENIA (2 patients)
FEMORAL NECK FRACTURE (2 patients)
FOOT FRACTURE (2 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (2 patients)
GANGRENE (2 patients)
GASTRIC ULCER HAEMORRHAGE (2 patients)
GINGIVAL HYPERTROPHY (2 patients)
GLOSSOPTOSIS (2 patients)
PLEURISY (2 patients)
PHRENIC NERVE PARALYSIS (2 patients)
HAEMATEMESIS (2 patients)
HAEMATURIA (2 patients)
HAEMOGLOBIN DECREASED (2 patients)
POLLAKIURIA (2 patients)
ORAL INTAKE REDUCED (2 patients)
HEPATIC CYST (2 patients)
HEPATIC ENCEPHALOPATHY (2 patients)
HEPATITIS (2 patients)
HYPERREFLEXIA (2 patients)
HYPERTONIA (2 patients)
HYPERURICAEMIA (2 patients)
RASH PAPULAR (2 patients)
INITIAL INSOMNIA (2 patients)
RETINAL OEDEMA (2 patients)
INTESTINAL FUNCTIONAL DISORDER (2 patients)
RESPIRATION ABNORMAL (2 patients)
IRRITABILITY (2 patients)
RIB FRACTURE (2 patients)
LEG AMPUTATION (2 patients)
LYMPHADENOPATHY (2 patients)
METABOLIC ALKALOSIS (2 patients)
ORAL HERPES (2 patients)
TAKAYASU'S ARTERITIS (2 patients)
MOUTH HAEMORRHAGE (2 patients)
UNRESPONSIVE TO STIMULI (2 patients)
TOXIC SKIN ERUPTION (2 patients)
NEPHROLITHIASIS (2 patients)
SUICIDE ATTEMPT (2 patients)
VENTRICULAR FIBRILLATION (2 patients)
NEUTROPHIL COUNT DECREASED (2 patients)
UPPER RESPIRATORY TRACT INFECTION (2 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (2 patients)
SHOCK HAEMORRHAGIC (2 patients)
ABDOMEN CRUSHING (1 patients)
CARDIAC FAILURE CONGESTIVE (1 patients)
EOSINOPHILIC PNEUMONIA ACUTE (1 patients)
ESSENTIAL TREMOR (1 patients)
WRONG TECHNIQUE IN DRUG USAGE PROCESS (1 patients)
FUNGAL INFECTION (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALMARL


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PLEURISY and ALMARL, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALMARL, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALMARL. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALMARL experts. If you are a healthcare provider experienced in prescribing ALMARL, please register here.

Your online appointment book for Seneca Rentals & Services

© 2014 FactMed, Inc
Privacy Policy
Terms of Use